Ionis Pharmaceuticals, Inc. (IONS) NASDAQ

71.19

-1.15(-1.59%)

Updated at March 13 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Brett Monia	Founder, Chief Executive Officer & Director	2.09M	1961
C. Frank Bennett	Executive VP & Chief Scientific Officer	651,639	1957
Kyle Jenne	Executive VP & Chief Global Product Strategy Officer	804,966	1976
Patrick R. O'Neil	Executive Vice President, Chief Legal Officer, General Counsel & Corporate Secretary	971,520	1974
Richard S. Geary	Executive VP & Chief Development Officer	1.01M	1958
Elizabeth L. Hougen	Executive VP of Finance & CFO	1.16M	1962
Darren Gonzales	Chief Accounting Officer & Senior Vice President	0	N/A
D. Wade Walke	Senior Vice President of Investor Relations	0	N/A
Hayley Soffer	Vice President of Corporate Communications	0	N/A
Tracy Berns	Senior VP and Chief Compliance & Quality Assurance Officer	0	N/A

Name

Title

Pay

Year Born

Brett Monia

Founder, Chief Executive Officer & Director

2.09M

1961

C. Frank Bennett

Executive VP & Chief Scientific Officer

651,639

1957

Kyle Jenne

Executive VP & Chief Global Product Strategy Officer

804,966

1976

Patrick R. O'Neil

Executive Vice President, Chief Legal Officer, General Counsel & Corporate Secretary

971,520

1974

Richard S. Geary

Executive VP & Chief Development Officer

1.01M

1958

Elizabeth L. Hougen

Executive VP of Finance & CFO

1.16M

1962

Darren Gonzales

Chief Accounting Officer & Senior Vice President

N/A

D. Wade Walke

Senior Vice President of Investor Relations

N/A

Hayley Soffer

Vice President of Corporate Communications

N/A

Tracy Berns

Senior VP and Chief Compliance & Quality Assurance Officer

N/A

Description

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.